Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2a, Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Activity of Small Mobile Stem Cells (SMS) Delivered Into the Lung as a Potential Organ Regeneration Therapy in Moderate to Severe Chronic Obstructive Pulmonary Disease (SORT-COPD Study II)

NCT07871890 is registered in ClinicalTrials.gov with SMSbiotech as lead sponsor.

NCT NCT07871890
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07871890 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2a, Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Activity of Small Mobile Stem Cells (SMS) Delivered Into the Lung as a Potential Organ Regeneration Therapy in Moderate to Severe Chronic Obstructive Pulmonary Disease (SORT-COPD Study II)
Lead sponsor
SMSbiotech
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
October 1, 2026
Completion date
December 31, 2027
Enrollment
125 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic obstructive lung disease